Real-Life Patterns of Exacerbations While on Inhaled Corticosteroids and Long-Acting Beta Agonists for Asthma over 15 Years
Abstract
:1. Introduction
2. Methods
3. Results
4. Discussion
Author Contributions
Funding
Conflicts of Interest
References
- Nurmagambetov, T.; Kuwahara, R.; Garbe, P. The Economic Burden of Asthma in the United States, 2008–2013. Ann. Am. Thorac. Soc. 2018, 15, 348–356. [Google Scholar] [CrossRef] [PubMed]
- Association, A.L. Asthma in Adults Fact Sheet. 2012. Available online: http://www.lung.org/lung-disease/asthma/resources/facts-and-figures/asthma-in-adults.html (accessed on 12 April 2019).
- Edwards, S.J.; von Maltzahn, R.; Naya, I.P.; Harrison, T. Budesonide/formoterol for maintenance and reliever therapy of asthma: A meta analysis of randomised controlled trials. Int. J. Clin. Pract. 2010, 64, 619–627. [Google Scholar] [CrossRef] [PubMed]
- Arfe, A.; Blasi, F.; Merlino, L.; Corrao, G. Respiratory drugs and macrolides prevent asthma exacerbations: A real-world investigation. Respir. Med. 2016, 119, 7–12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Burden, A.; Roche, N.; Miglio, C.; Hillyer, E.V.; Postma, D.S.; Herings, R.M.; Overbeek, J.A.; Khalid, J.M.; van Eickels, D.; Price, D.B. An evaluation of exact matching and propensity score methods as applied in a comparative effectiveness study of inhaled corticosteroids in asthma. Pragmat. Obs. Res. 2017, 8, 15–30. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vervloet, M.; van Dijk, L.; Spreeuwenberg, P.; Price, D.; Chisholm, A.; Van Ganse, E.; Pinnock, H.; Rand, C.S.; Eakin, M.N.; Schermer, T.; et al. The Relationship Between Real-World Inhaled Corticosteroid Adherence and Asthma Outcomes: A Multilevel Approach. J. Allergy Clin. Immunol. Pract. 2020, 8, 626–634. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Demarche, S.F.; Schleich, F.N.; Henket, M.A.; Paulus, V.A.; Van Hees, T.J.; Louis, R.E. Effectiveness of inhaled corticosteroids in real life on clinical outcomes, sputum cells and systemic inflammation in asthmatics: A retrospective cohort study in a secondary care centre. BMJ Open 2017, 7, e018186. [Google Scholar] [CrossRef] [PubMed]
- Schmidt, O.; Petro, W.; Hoheisel, G.; Kanniess, F.; Oepen, P.; Langer-Brauburger, B. Real-life effectiveness of asthma treatment with a fixed-dose fluticasone/formoterol pressurised metered-dose inhaler—Results from a non-interventional study. Respir. Med. 2017, 131, 166–174. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Backer, V.; Ellery, A.; Borzova, S.; Lane, S.; Kleiberova, M.; Bengtsson, P.; Tomala, T.; Basset-Stheme, D.; Bennett, C.; Lindner, D.; et al. Non-interventional study of the safety and effectiveness of fluticasone propionate/formoterol fumarate in real-world asthma management. Ther. Adv. Respir. Dis. 2018, 12, 1753466618796987. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Suissa, S.; Dell’Aniello, S.; Ernst, P. Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice. Chest 2019, 115(6), 1158–1165. [Google Scholar] [CrossRef] [PubMed]
- Samp, J.C.; Joo, M.J.; Schumock, G.T.; Calip, G.S.; Pickard, A.S.; Lee, T.A. Comparative Effectiveness of Long-Acting Beta2 -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease. Pharmacotherapy 2017, 37, 447–455. [Google Scholar] [CrossRef] [PubMed]
- Suissa, S.; Dell’Aniello, S.; Ernst, P. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: A population-based cohort study. Lancet Respir. Med. 2018, 6, 855–862. [Google Scholar] [CrossRef]
- Marceau, C.; Lemiere, C.; Berbiche, D.; Perreault, S.; Blais, L. Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma. J. Allergy Clin. Immunol. 2006, 118, 574–581. [Google Scholar] [CrossRef] [PubMed]
- Banda, Y.; Kvale, M.N.; Hoffmann, T.J.; Hesselson, S.E.; Ranatunga, D.; Tang, H.; Sabatti, C.; Croen, L.A.; Dispensa, B.P.; Henderson, M.; et al. Characterizing Race/Ethnicity and Genetic Ancestry for 100,000 Subjects in the Genetic Epidemiology Research on Adult Health and Aging (GERA) Cohort. Genetics 2015, 200, 1285–1295. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cox, E.; Martin, B.C.; Van Staa, T.; Garbe, E.; Siebert, U.; Johnson, M.L. Good research practices for comparative effectiveness research: Approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report—Part II. Value Health 2009, 12, 1053–1061. [Google Scholar] [PubMed]
- Donahue, J.G.; Weiss, S.T.; Livingston, J.M.; Goetsch, M.A.; Greineder, D.K.; Platt, R. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997, 277, 887–891. [Google Scholar] [CrossRef] [PubMed]
- Wu, A.C.; Li, L.; Fung, V.; Kharbanda, E.O.; Larkin, E.K.; Vollmer, W.M.; Butler, M.G.; Miroshnik, I.; Rusinak, D.; Davis, R.L.; et al. Use of leukotriene receptor antagonists are associated with a similar risk of asthma exacerbations as inhaled corticosteroids. J. Allergy Clin. Immunol. Pract. 2014, 2, 607–613. [Google Scholar] [CrossRef] [PubMed]
- Stoloff, S.W.; Stempel, D.A.; Meyer, J.; Stanford, R.H.; Carranza Rosenzweig, J.R. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J. Allergy Clin. Immunol. 2004, 113, 245–251. [Google Scholar] [CrossRef] [PubMed]
- Turner, S.; Richardson, K.; Murray, C.; Thomas, M.; Hillyer, E.V.; Burden, A.; Price, D.B.; Group, R.E. Long-Acting beta-Agonist in Combination or Separate Inhaler as Step-Up Therapy for Children with Uncontrolled Asthma Receiving Inhaled Corticosteroids. J. Allergy Clin. Immunol Pract. 2017, 5, 99–106. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mapel, D.W.; Roberts, M.H. Management of asthma and chronic obstructive pulmonary disease with combination inhaled corticosteroids and long-acting beta-agonists: A review of comparative effectiveness research. Drugs 2014, 74, 737–755. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Psaty, B.M.; Siscovick, D.S. Minimizing bias due to confounding by indication in comparative effectiveness research: The importance of restriction. JAMA 2010, 304, 897–898. [Google Scholar] [CrossRef] [PubMed]
Retained | Excluded | p-Value | |
---|---|---|---|
N | 1844 | 11,917 | |
Age (years) | 64.00 (+/−11.37) | 63.66 (+/−13.21) | 0.29 |
Weight (kg) | 80.9 (+/−19.2) | 80.0 (+/−19.2) | 0.065 |
Smoking | |||
Never | 796 (43.17%) | 6326 (53.08%) | 0.23 |
Former | 851 (46.15%) | 4578 (38.42%) | 0.019 |
Current | 113 (6.13%) | 529 (4.44%) | 1.30 × 10−13 |
Height (in) | 65.76 (+/−23.62) | 63.98 (+/−45.22) | 0.1 |
Gender (n Male) | 696 (37.74%) | 3879 (32.55%) | 1.10 × 10−5 |
Race/ethnicity | |||
Asian | 111 (6.02%) | 883 (7.41%) | 0.032 |
Black | 83 (4.50%) | 467 (3.92%) | 0.23 |
Hispanic | 127 (6.89%) | 1013 (8.50%) | 0.019 |
Other | 15 (0.81%) | 88 (0.74%) | 0.73 |
White | 1508 (81.78%) | 9466 (79.43%) | 0.02 |
Total Days Observed | 3391 (+/−866) | 2405 (+/−1277) | 3.20 × 10−217 |
Total Days Not Covered | 1543 (+/−808) | 1736 (+/−1137) | 2.10 × 10−12 |
Total Bursts | 7.67 (+/−9.86) | 2.56 (+/−5.74) | 5.40 × 10−213 |
Total Hospitalizations | 1.57 (+/−2.78) | 0.80 (+/−1.94) | 4.20 × 10−49 |
Total ED visits | 2.21 (+/−4.10) | 1.12 (+/−3.28) | 4.20 × 10−37 |
Days covered by OCS | 0.05 (+/−0.11) | 0.03 (+/−0.10) | 3.30 × 10−13 |
Days covered by ICS | 0.15 (+/−0.17) | 0.20 (+/−0.23) | 7.80 × 10−19 |
Days covered by Montelukast | 0.10 (+/−0.20) | 0.06 (+/−0.18) | 3.30 × 10−24 |
Days covered by ICS–LABA combination | 0.37 (+/−0.20) | 0.03 (+/−0.13) | 0 |
Total Exacs on ICS | 1.83 (+/−3.73) | 0.99 (+/−2.45) | 2.10 × 10−36 |
Total Exacs on Montelukast | 1.38 (+/−4.06) | 0.34 (+/−2.13) | 4.30 × 10−62 |
Total Exacs on ICS–LABAs | 4.04 (+/−5.56) | 0.27 (+/−1.95) | 0 |
Bursts covered by ICS | 1.22 (+/−2.47) | 0.54 (+/−1.55) | 1.20 × 10−56 |
Bursts covered by Montelukast | 0.90 (+/−2.72) | 0.20 (+/−1.25) | 4.00 × 10−73 |
Bursts covered by ICS–LABAs | 2.54 (+/−3.68) | 0.16 (+/−1.16) | 0 |
ED/Hosps covered by ICS | 0.61 (+/−1.90) | 0.45 (+/−1.36) | 8.40 × 10−6 |
ED/Hosps covered by Montelukast | 0.48 (+/−1.90) | 0.14 (+/−1.19) | 1.00 × 10−24 |
ED/Hosps covered by ICS–LABAs | 1.50 (+/−2.90) | 0.12 (+/−1.05) | 5.20 × 10−303 |
ED/Hosps covered by OCS | 0.41 (+/−1.84) | 0.13 (+/−1.69) | 1.40 × 10−10 |
No Exacerbations on ICS/LABAs | Exacerbations on ICS/LABAs | p-Value | |
---|---|---|---|
N | 549 | 1295 | |
Age (years) | 62.29 (+/−11.85) | 64.73 (+/−11.09) | 2.30 × 10−5 |
Weight (kg) | 78.77 (+/−18.3) | 81.87 (+/−19.6) | 0.0018 |
Smoking | |||
Never | 238 (43.35%) | 558 (43.09%) | 0.92 |
Former | 254 (46.27%) | 597 (46.10%) | 0.95 |
Current | 38 (6.92%) | 75 (5.79%) | 0.35 |
Height (in) | 66.29 (+/−3.84) | 65.54 (+/−28.07) | 0.54 |
Gender (n Male) | 196 (35.70%) | 500 (38.61%) | 0.24 |
Race/ethnicity | |||
White | 459 (83.61%) | 1049 (81.00%) | 0.19 |
Asian | 31 (5.65%) | 80 (6.18%) | 0.66 |
Black | 21 (3.83%) | 62 (4.79%) | 0.36 |
Hispanic | 33 (6.01%) | 94 (7.26%) | 0.33 |
Other | 5 (0.91%) | 10 (0.77%) | 0.76 |
Total Days Observed | 3327.22 (+/−874.55) | 3419.35 (+/−861.36) | 0.037 |
Total Days Not Covered | 1374.14 (+/−784.18) | 1615.23 (+/−807.89) | 4.10 × 10−9 |
Total Bursts | 1.97 (+/−3.58) | 10.09 (+/−10.65) | 3.20 × 10−63 |
Total Hospitalizations | 0.42 (+/−0.85) | 2.06 (+/−3.14) | 4.10 × 10−32 |
Total ED visits | 0.60 (+/−1.12) | 2.89 (+/−4.67) | 5.90 × 10−29 |
Days covered by OCS | 0.01 (+/−0.04) | 0.06 (+/−0.12) | 1.00 × 10−21 |
Days covered by ICS | 0.16 (+/−0.19) | 0.14 (+/−0.16) | 0.0028 |
Days covered by Montelukast | 0.11 (+/−0.22) | 0.10 (+/−0.19) | 0.37 |
Days covered by ICS–LABA combination | 0.39 (+/−0.22) | 0.36 (+/−0.19) | 0.0015 |
Total Exacs on ICS | 0.74 (+/−1.69) | 2.29 (+/−4.23) | 2.40 × 10−16 |
Total Exacs on Montelukast | 0.53 (+/−1.92) | 1.74 (+/−4.63) | 4.50 × 10−9 |
Total Exacs on ICS–LABAs | 1.25 (+/−2.38) | 5.22 (+/−6.07) | 3.50 × 10−47 |
Bursts covered by ICS | 0.50 (+/−1.34) | 1.53 (+/−2.77) | 2.10 × 10−16 |
Bursts covered by Montelukast | 0.36 (+/−1.46) | 1.12 (+/−3.08) | 3.40 × 10−8 |
Bursts covered by ICS–LABAs | 0.78 (+/−1.72) | 3.28 (+/−4.02) | 1.30 × 10−42 |
ED/Hosps covered by ICS | 0.25 (+/−0.71) | 0.76 (+/−2.21) | 8.40 × 10−8 |
ED/Hosps covered by Montelukast | 0.17 (+/−0.73) | 0.61 (+/−2.21) | 4.20 × 10−6 |
ED/Hosps covered by ICS–LABAs | 0.47 (+/−1.04) | 1.94 (+/−3.30) | 6.80 × 10−24 |
ED/Hosps covered by OCS | 0.03 (+/−0.19) | 0.57 (+/−2.17) | 6.40 × 10−9 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
McGeachie, M.J.; Wang, A.L.; Lutz, S.M.; Sordillo, J.E.; Weiss, S.T.; Tantisira, K.G.; Iribarren, C.; Lu, M.X.; Wu, A.C. Real-Life Patterns of Exacerbations While on Inhaled Corticosteroids and Long-Acting Beta Agonists for Asthma over 15 Years. J. Clin. Med. 2020, 9, 819. https://doi.org/10.3390/jcm9030819
McGeachie MJ, Wang AL, Lutz SM, Sordillo JE, Weiss ST, Tantisira KG, Iribarren C, Lu MX, Wu AC. Real-Life Patterns of Exacerbations While on Inhaled Corticosteroids and Long-Acting Beta Agonists for Asthma over 15 Years. Journal of Clinical Medicine. 2020; 9(3):819. https://doi.org/10.3390/jcm9030819
Chicago/Turabian StyleMcGeachie, Michael J., Alberta L. Wang, Sharon M. Lutz, Joanne E. Sordillo, Scott T. Weiss, Kelan G. Tantisira, Carlos Iribarren, Meng X. Lu, and Ann Chen Wu. 2020. "Real-Life Patterns of Exacerbations While on Inhaled Corticosteroids and Long-Acting Beta Agonists for Asthma over 15 Years" Journal of Clinical Medicine 9, no. 3: 819. https://doi.org/10.3390/jcm9030819